Find new investment opportunities based on Market Sentiment Indicator. Manage watchlist risk with leading indicator of volatility See what influential analysts and investors are saying about stocks in your watchlist
Most Trending
-2.92%
-2.08%
+9.79%
-19.01%
-3.34%
PRME
Prime Medicine Inc.
$1.18
Chart
$1.39 (-15.11%)
$2.4 (-50.83%)
$3.26 (-63.80%)
$7.11 (-83.40%)
FIND US ON
Join over 10,000+ subscribers who value exclusive insights. Stay ahead in the stock market! Enter your email for daily alerts
Stay ahead of the market
Market trends
Investment tips
Market analysis service
Future potential
Informed investment decisions
Investment analysis
IInvestment strategies
In-depth stock analysis
Performance analysis
Stock market insights
Financial trends analysis
Most Trending
-2.92%
-2.08%
+9.79%
-19.01%
-3.34%
PRME
Prime Medicine Inc.
Current Price
$1.18
Login to view Prime Medicine Inc. (PRME) recommendation from the last 90 days from financial news and social media.
Chart
$1.39 (-15.11%)
$2.4 (-50.83%)
$3.26 (-63.80%)
$7.11 (-83.40%)
PRME Latest Headlines
Prime Medicine to Participate in Upcoming Investor Conferences. CAMBRIDGE Mass. May 29 2025 (GLOBE NEWSWIRE) -- Prime Medicine Inc. (NASDAQ:) a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies today announced that company management will participate in the following upcoming conferences:Live audio webcasts of each presentation will be available under Events &. Presentations in the News &. Events section of the Company'.s we
Thu May 29, 2025
6 Analysts Assess Prime Medicine: What You Need To Know. 6 analysts have shared their evaluations of Prime Medicine (NASDAQ:) during the recent three months expressing a mix of ish and bearish perspectives.The table below provides a snapshot of their recent ratings showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.5100010000000001000031000The 12-month price targets analyzed by analysts offer insights with an average target of $12.17 a high es
Mon May 19, 2025
Prime Medicine Prioritizes Pipeline Cuts Workforce By 25% - Stock Plunges . (RTTNews) - Shares of Prime Medicine Inc. (PRME) are down over 17% today after the company announced a strategic restructuring aimed at focusing on key areas such as large genetic liver diseases cystic fibrosis and partnered programs along with a transition in CEO leadership
Mon May 19, 2025
Prime Medicine Prioritizes Pipeline Cuts Workforce By 25% - Stock Plunges . (RTTNews) - Shares of Prime Medicine Inc. (PRME) are down over 17% today after the company announced a strategic restructuring aimed at focusing on key areas such as large genetic liver diseases cystic fibrosis and partnered programs along with a transition in CEO leadership
Mon May 19, 2025
Prime Medicine drops after cutting CGD program amid restructuring.
Mon May 19, 2025
Prime Medicine drops after cutting CGD program amid restructuring.
Mon May 19, 2025
FIND US ON
Unlock the knowledge that 10,000+ subscribers already cherish. Join for exclusive insights and stay ahead in the stock game! Enter your email to receive daily alerts
In-depth stock analysis
Informed investment decisions
Stock market insights
Stock trading tips
PRME Stock trends
PRME Stock performance
PRME Stock analysis
PRME investment strategies
Disclaimer:
Past performance, whether from actual results or historical strategy tests, does not guarantee future success. The displayed outcomes are based on strategies not previously available to investors and do not depict the returns achieved by any specific investor.
The Readiness Indicators, Sentiment Indicators, and overall score are derived from a model retrospectively applied using historical data. This model relies on assumptions inherent to it, which may or may not be verifiable and carry potential risks, including losses.
Engaging in active trading may not be suitable for individuals with limited resources, minimal investment or trading experience, or a low-risk tolerance. Proceed with caution as your capital is exposed to risks.
Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").
This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.
Hover over the category for more information
